AI Article Synopsis
- Research is needed for non-hormonal therapies for women who can't or choose not to use menopausal hormone therapy.
- One promising option is purified cytoplasmic pollen extract, or PureCyTonin, which has shown safety and effectiveness in alleviating menopausal symptoms in clinical studies.
- PureCyTonin works similarly to SSRIs and lacks estrogenic effects, making it potentially suitable for women with breast cancer as well.
Article Abstract
Research into non-hormonal, alternative therapies is necessary for women for whom menopausal hormone therapy is contraindicated or for women who do not wish to take hormones. This review focuses on one such non-hormonal option, namely, purified and specific cytoplasmic pollen extract, or PureCyTonin. This extract has been evaluated in several preclinical and clinical studies, where it demonstrated its value as a safe and non-estrogenic alternative for menopause. This review presents the beneficial effects of PureCyTonin in the treatment of menopausal symptoms (e.g. hot flushes) in healthy women, as well as in premenstrual syndrome. We discuss the mechanism of action of PureCyTonin, an SSRI-'like' therapy. The lack of estrogenic effect demonstrated in preclinical studies suggests that PureCyTonin may also be a suitable option for the management of menopausal symptoms in women with breast cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09513590.2020.1722994 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of vaginal estrogen on serum estradiol during aromatase inhibitor therapy in breast cancer patients with vulvovaginal atrophy: a prospective trial.
Breast Cancer Res Treat
December 2024
Comprehensive Cancer Center, Helsinki University Hospital, University of Helsinki, PO Box 180, 00290, Helsinki, Finland.
Purpose: This study aimed to analyze changes in serum estradiol (E2) levels during concurrent vaginal estradiol therapy and adjuvant letrozole in postmenopausal breast cancer (BC) patients with vulvovaginal atrophy (VVA). Secondary objectives included assessing the effects of therapy on vaginal atrophy, quality of life (QoL) and menopause-related symptoms.
Methods: 20 postmenopausal patients undergoing adjuvant letrozole therapy and experiencing VVA symptoms were treated with vaginal estradiol for 12 weeks.
A cultural adaptation and testing on the reliability and validity of the Chinese version of the Menopause Symptom Assessment Scale.
Menopause
January 2025
From the Department of Quality Control, Yuebei People's Hospital, Shantou University Medical College, Shaoguan, China.
Objective: The aim of this study was to modify the Chinese version of the Menopause Symptom Assessment Scale (MSAS) and evaluate its validity and reliability.
Methods: An expert panel from the gynecology and nursing domain determined items that should remain or be revised, and 30 participants were selected for the pilot study. A total of 255 women who met the criteria for inclusion were enrolled in the investigation.
Jazz dancing for improving cardiorespiratory fitness, body composition, muscle strength, and sleep quality in postmenopausal women: a randomized clinical trial with 6- and 12-month follow-ups.
Menopause
January 2025
From the Department of Physiotherapy, Santa Catarina State University, Florianópolis, Brazil.
Objective: The aim of the study was to analyze the effects of 16 weeks of Jazz Dance training compared to a control group in postmenopausal women, postintervention, and at the 6- and 12-month follow-ups, on cardiorespiratory fitness, body composition, muscle strength, and sleep quality.
Methods: Two-arm randomized clinical trial with a total of 47 women (jazz dance intervention group [JDIG] [n = 23] and control group (CG) [n = 24]) with a mean age of 53.41 ± 2.
Prevalence and impact of vasomotor symptoms due to menopause among women in Canada: A subgroup analysis from an international cross-sectional survey of Women with Vasomotor Symptoms Associated with Menopause (WARM Study).
Menopause
January 2025
Clinique de Recherche en Santé des Femmes, Québec City, Québec, Canada.
Objective: The aim of the study was to assess the prevalence of postmenopausal vasomotor symptoms (VMS) and the impact of VMS and related treatment patterns among perimenopausal and postmenopausal Canadian women.
Methods: A subgroup analysis of data from a cross-sectional online survey of women aged 40-65 years conducted November 4, 2021, through January 17, 2022, evaluated the prevalence of moderate/severe VMS among postmenopausal Canadian women. The analysis also assessed survey responses from perimenopausal and postmenopausal Canadian women with moderate/severe VMS who completed the Menopause-Specific Quality of Life questionnaire, Work Productivity and Activity Impairment questionnaire, and the Patient-Reported Outcomes Measurement Information System Sleep Disturbances-Short Form 8b and answered questions about treatment patterns and attitudes toward treatments.
Associations of blood pressure with white matter hyperintensities later in life; influence of short-term menopausal hormone therapy.
Menopause
January 2025
From the Department of Radiology, Mayo Clinic, Rochester, MN.
Objective: To assess the association of systolic and diastolic blood pressure (SBP and DBP) in recently menopausal women with white matter hyperintensity (WMH) volume later in life and determine whether short-term menopausal hormone therapy (mHT) modifies these associations.
Methods: Kronos Early Estrogen Prevention Study (KEEPS) was a multicenter, randomized, double-blinded, placebo-controlled 4-year mHT trial (oral conjugated equine estrogens or transdermal 17β-estradiol). KEEPS continuation was an observational follow-up of the participants 10 years after the end of mHT.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!